PROTHENA CORPORATION PUBLIC LIMITED COMPANY Deferred Revenue
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Deferred Revenue of $620.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-08-06
- 2026-06-30: Deferred Revenue, Current $620.00K.
- 2026-03-31: Deferred Revenue, Current $1.63M.
- 2025-12-31: Deferred Revenue, Current $2.66M.
- 2025-09-30: Deferred Revenue, Current $2.69M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2026-06-30 | $620.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.63M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.66M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.69M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.10M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $7.90M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $8.85M 10-K · filed 2026-02-27 |
| 2024-09-30 | $8.83M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $8.03M 10-Q · filed 2024-08-08 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2023-09-30 | $316.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $25.12M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $9.32M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $11.44M 10-K · filed 2024-02-22 |
| 2022-09-30 | $9.66M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $9.82M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $8.84M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $7.66M 10-K · filed 2023-02-28 |
| 2021-09-30 | $7.21M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $24.95M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |